```
=> d his

     (FILE 'HOME' ENTERED AT 20:39:00 ON 16 SEP 2002)

     FILE 'MEDLINE, BIOSIS' ENTERED AT 20:41:49 ON 16 SEP 2002
L1             5 S IL-17C
L2             3 DUP REM L1 (2 DUPLICATES REMOVED)
L3             0 S PRO1122
L4         16449 S (CHEN, J?)/AU
L5             2 S L1 AND L4
L6             1 S L2 AND L4
L7             0 S IL-171
L8            46 S IL-21
L9            38 DUP REM L8 (8 DUPLICATES REMOVED)
L10            0 S L9 AND IL-17
L11           18 S L9 AND PY<2000
L12            0 S PRO1031
```

EAST - [IL-17 homol (Chen).wsp:1]

File View Edit Tools Window Help

- Drafts
- Pending
- Active
  - L4: (9) IL-17 adj (like homol$ relat$)
  - L5: (103598) Chen
  - L6: (49764) Chen.in.
  - L8: (86) IL adj "21"
  - L9: (5) l6 and IL-17
  - L10: (5) l6 and IL adj "17"
  - L7: (6) l6 and PRO1122
- Failed
- Saved
  - (5) IL-17C
  - (17) PRO1122
  - (16) PRO1031
- Favorites
- Tagged (0)
- UDC
- Queue
- Trash

Search | List | Browse | Queue | Clear

DBs: USPAT; US-PGPUB; EPO; JPO; DERWENT | Plurals

Default operator: OR | Highlight all hit terms initially

16 and PRO1122

BRS form | ISR form | Image | Text | HTML

	U	1	Document ID	Issue Dat	Pages	Title	Current OR	Current XR	Retrieval	Inventor	S	C	P				
1	☐	☐	US 20020127584	20020912	701	Secreted and transmembrane polypepti	435/6	435/183; 435/320.1;		Baker, Kevin P. et al.	☑	☐	☐	☐	☐	☐	☐
2	☑	☐	US 20020106743	20020808		IL-17 homologous polypeptides and therap	435/69.52	435/320.1; 435/325;		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
3	☑	☐	US 20020052027	20020502		IL-17 homologous polypeptides and therap	435/69.5	435/320.1; 435/325;		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
4	☑	☐	US 20020010137	20010628		Novel PRO polypeptides homologous to interleuk				ASHKENAZI, A et al.	☐	☐	☐	☐	☐	☐	☐
5	☑	☐	US 20020010137	20000323		Novel nucleic acids encoding secreted and t				ASHKENAZI, A et al.	☐	☐	☐	☐	☐	☐	☐
6	☑	☐	US 20020052027	19991125		New polypeptides designated PRO1031 and				CHEN, J et al.	☐	☐	☐	☐	☐	☐	☐

Hits | Details | HTML

Ready

NUM

GenCore version 4.5

OM protein - protein search, using sw model

Run on: September 16, 2002, 15:41:36 ; Search time 30.37 Seconds
(without alignments)
720.498 Million cell updates/sec

Title: US-09-854-208-3
Perfect score: 1073
Sequence: 1 MTLLPGLLFLTWLHTCLAHH.....FHTEFIHVPVGCTCVLPRSV 197

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_032802:*
1: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/hold-geneseq/geneseqp-embl/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1073	100.0	197	21	AAB18911	A novel polypeptid
2	1073	100.0	197	21	AAB07602	A human interleuki
3	1073	100.0	197	21	AAB07684	A human interleuki
4	1073	100.0	197	21	AAY92238	Human interleukin-
5	1073	100.0	197	21	AAY44460	Human Interleukin
6	1073	100.0	197	21	AAY53892	Amino acid sequenc
7	1073	100.0	197	22	AAG66121	Human interleukin
8	1073	100.0	197	22	AAU29247	Human PRO polypept
9	1073	100.0	197	22	AAU04951	Human Interleukin
10	1073	100.0	206	21	AAY44485	Human Interleukin
11	1073	100.0	425	21	AAY44462	Human Interleukin
12	1063	99.1	227	22	AAE08676	Human interleukin
13	1061	98.9	227	22	AAE08680	Human interleukin
14	1061	98.9	227	22	AAE08682	Human interleukin
15	1060	98.8	227	22	AAE08681	Human interleukin
16	1060	98.8	227	22	AAE08685	Human interleukin
17	1059	98.7	227	22	AAE08684	Human interleukin
18	1059	98.7	227	22	AAE08687	Human interleukin
19	1058	98.6	227	22	AAE08679	Human interleukin
20	1058	98.6	227	22	AAE08683	Human interleukin
21	1058	98.6	227	22	AAE08686	Human interleukin
22	1055	98.3	227	22	AAE08690	Human interleukin
23	1054	98.2	227	22	AAE08688	Human interleukin
24	1054	98.2	227	22	AAE08689	Human interleukin
25	1054	98.2	227	22	AAE08691	Human interleukin
26	1054	98.2	227	22	AAE08693	Human interleukin
27	1054	98.2	227	22	AAE08695	Human interleukin
28	1054	98.2	227	22	AAE08697	Human interleukin
29	1054	98.2	227	22	AAE08699	Human interleukin
30	1054	98.2	227	22	AAE08701	Human interleukin
31	1054	98.2	227	22	AAE08703	Human interleukin
32	1053	98.1	227	22	AAE08692	Human interleukin
33	1053	98.1	227	22	AAE08694	Human interleukin
34	1053	98.1	227	22	AAE08696	Human interleukin
35	1053	98.1	227	22	AAE08698	Human interleukin
36	1053	98.1	227	22	AAE08700	Human interleukin
37	1053	98.1	227	22	AAE08702	Human interleukin
38	1034	96.4	223	22	AAE08677	Human mature inter
39	459	42.8	87	21	AAY53890	Partial amino acid
40	459	42.8	87	22	AAG66119	Human interleukin
41	446	41.6	123	21	AAB07601	A human interleuki
42	446	41.6	123	21	AAB07683	A human interleuki
43	199	18.5	202	21	AAB07595	A human interleuki
44	199	18.5	202	21	AAB07689	A human interleuki
45	199	18.5	202	21	AAY70653	Human transforming

ALIGNMENTS

RESULT 1
AAB18911
ID AAB18911 standard; Protein; 197 AA.
XX
AC AAB18911;
XX
DT 08-FEB-2001 (first entry)
XX
DE A novel polypeptide designated PRO1122.
XX
KW Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
KW PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW insulinemia; kidney disorder; Bergers disease; nephropathy;
KW Schonlein-Henoch purpura; celiac disease; dermatitis herpetiformis;
KW Crohns disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..18
FT /note= "signal peptide"
FT Region 3..25
FT /note= "leucine zipper pattern"
FT Modified-site 32..38
FT /note= "N-myristoylation site"
FT Modified-site 55..61
FT /note= "N-myristoylation site"
FT Modified-site 112..121
FT /note= "tyrosine kinase phosphorylation site"
FT Modified-site 133..139
XX
PN WO200056889-A2.

```
XX
PD   28-SEP-2000.
XX
PF   01-MAR-2000; 2000WO-US05601.
XX
PR   23-MAR-1999;   99US-0125774.
PR   23-MAR-1999;   99US-0125778.
PR   24-MAR-1999;   99US-0125826.
PR   31-MAR-1999;   99US-0127035.
PR   05-APR-1999;   99US-0127706.
PR   21-APR-1999;   99US-0130359.
PR   27-APR-1999;   99US-0131270.
PR   27-APR-1999;   99US-0131272.
PR   27-APR-1999;   99US-0131291.
PR   04-MAY-1999;   99US-0132371.
PR   04-MAY-1999;   99US-0132379.
PR   04-MAY-1999;   99US-0132383.
PR   25-MAY-1999;   99US-0135750.
PR   08-JUN-1999;   99US-0138166.
PR   20-JUL-1999;   99US-0144791.
PR   03-AUG-1999;   99US-0146970.
PR   09-DEC-1999;   99US-0170262.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Desnoyers L,  Eaton DL,  Goddard A,  Godowski PJ,  Gurney AL,  Pan J;
PI   Stewart TA,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2000-628263/60.
DR   N-PSDB; AAA96338.
XX
PT   Novel secreted and transmembrane polypeptides useful for diagnosing
PT   tumour in a mammal, for identifying agonists and antagonists of the
PT   polypeptide and for therapeutic use -
XX
PS   Claim 12; Fig 6; 222pp; English.
XX
CC   The present sequence represents a secreted or transmembrane polypeptide.
CC   The specification describes polypeptides designated PRO1484, PRO4334,
CC   PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
CC   PRO4356, PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
CC   PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
CC   useful for diagnosing tumour in a mammal. The polypeptides, their
CC   agonists and antagonists are useful treating a condition associated with
CC   expression or activity of the polypeptide. Conditions treated include
CC   obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
CC   capable of inducing proliferation of mammalian kidney mesangial cells
CC   and are therefore useful for treating kidney disorders associated with
CC   decreased mesangial cell function such as Bergers disease or other
CC   nephropathies associated with Schonlein-Henoch purpura, celiac disease,
CC   dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
CC   to generate transgenic animals for use in development and screening of
CC   therapeutically useful reagents and also for chromosome identification
CC   and tissue typing.
XX
SQ   Sequence   197 AA;

  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy      61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy     121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy     181 EFIHVPVGCTCVLPRSV 197
           |||||||||||||||||
Db     181 efihvpvgctcvlprsv 197


RESULT   2
AAB07602
ID   AAB07602 standard; Protein; 197 AA.
XX
AC   AAB07602;
XX
DT   07-NOV-2000  (first entry)
XX
DE   A human interleukin (IL) 171 polypeptide.
XX
KW   Interleukin; IL-17; CTLA-8; IL-170; IL-172; IL-173; IL-174; IL-176;
KW   IL-177; IL-171; cell proliferation; cancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..17
FT                   /note= "signal peptide"
FT   Protein         18..197
FT                   /note= "mature protein"
XX
PN   WO200042188-A2..
XX
PD   20-JUL-2000.
XX
PF   10-JAN-2000; 2000WO-US00006.
XX
PR   11-JAN-1999;   99US-0228822.
XX
PA   (SCHE ) SCHERING CORP.
XX
PI   Gorman DM,  Bazan JF,  Kastelein RA;
XX
DR   WPI; 2000-466130/40.
DR   N-PSDB; AAA58991.
XX
PT   New isolated polynucleotide encoding a mammalian Interleukin-17 like
PT   protein used to identify genes for homologous proteins -
XX
PS   Disclosure; Page 20-21; 111pp; English.
XX
CC   The present sequence represents an interleukin-171 (IL-171) polypeptide.
CC   The polypeptide is an IL-17-like (CTLA-8 related) protein. It is a
CC   member of a new group of interleukins, IL-170 polypeptides. The members
CC   comprise IL-172, IL-173, IL-174, IL-176, IL-177, and IL-171. IL-170
CC   protein can be used to treat abnormal proliferation e.g. cancer
CC   or degenerative conditions. Antibodies can be used in diagnostic
CC   methods to detect over production of IL-170 protein in cells or body
CC   fluids.
XX
SQ   Sequence   197 AA;

  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy      61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy     121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db    121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT   3
AAB07684
ID   AAB07684 standard; Protein; 197 AA.
XX
AC   AAB07684;
XX
DT   07-NOV-2000  (first entry)
XX
DE   A human interleukin-171 polypeptide.
XX
KW   Interleukin; IL-171; cytokine; CTLA-8; IL-17; IL-175; IL-172; IL-173;
KW   IL-174; IL-176; IL-177; cell proliferation; cancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..17
FT                   /note= "signal peptide"
FT   Protein         18..197
FT                   /note= "mature protein"
FT   Modified-site   55..57
FT                   /note= "putative glycosylation site"
XX
PN   WO200042187-A1.
XX
PD   20-JUL-2000.
XX
PF   10-JAN-2000; 2000WO-US00005.
XX
PR   11-JAN-1999;   99US-0229402.
XX
PA   (SCHE ) SCHERING CORP.
XX
PI   Gorman DM,  Bazan JF,  Kastelein RA;
XX
DR   WPI; 2000-476060/41.
DR   N-PSDB; AAA59149.
XX
PT   New DNA sequence encoding a mammalian homolog of CTLA-8, designated
PT   interleukin-171 (IL-171), useful for recombinant production of IL-171
PT   which can be used for treating conditions associated with abnormal
PT   physiology or development -
XX
PS   Claim 11; Page 10-11; 111pp; English.
XX
CC   The present sequence represents an interleukin (IL)-171 polypeptide.
CC   It is a mammalian homologue of the cytokine designated CTLA-8 (also
CC   referred to as IL-17). The specification also describes homologues
CC   IL-171, IL-175, IL-172, IL-173, IL-174, IL-176, and IL-177. The DNA
CC   sequence encoding IL-171 is useful for identifying genes, mRNA and
CC   cDNA molecules which code for related or homologous proteins. The
CC   IL-171 protein, antibodies against IL-171, and compounds which have
CC   binding affinity to IL-171 are useful in treatment of conditions
CC   associated with abnormal physiology or development, including abnormal
CC   proliferation, e.g. cancerous conditions, or degenerative conditions.
CC   The IL-171 protein can be used in kits and assay methods for identifying
CC   compounds that selectively bind to IL-171.
XX
SQ   Sequence   197 AA;


  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT   4
AAY92238
ID   AAY92238 standard; Protein; 197 AA.
XX
AC   AAY92238;
XX
DT   10-AUG-2000  (first entry)
XX
DE   Human interleukin-17 (IL-17) homologue.
XX
KW   Interleukin 17; IL-17; haematopoiesis; chemotherapy; cytostatic;
KW   antianemic; cardiant; hemostatic; anti-inflammatory; anti-HIV.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /label= signal_peptide
FT   Protein         19..197
FT                   /label= mature_protein
XX
PN   WO200020593-A1.
XX
PD   13-APR-2000.
XX
PF   30-SEP-1999;   99WO-US22678.
XX
PR   02-OCT-1998;   98US-0102883.
PR   01-DEC-1998;   98US-0110405.
PR   11-JUN-1999;   99US-0138910.
XX
PA   (ELIL ) LILLY & CO ELI.
XX
PI   Glasebrook AL,  Su EW,  Wei J,  Liu L;
XX
DR   WPI; 2000-303778/26.
DR   N-PSDB; AAA09153.
XX
PT   Nucleic acid encoding an interleukin-17 (IL-17) homolog polypeptide
PT   which enhances hematopoiesis, useful for treating e.g. anemia,
PT   thrombocytopenia, viral and bacterial infections
XX
PS   Claim 16; Page 92-93; 111pp; English.
XX
CC   Interleukin 17 (IL-17) stimulates hematopoiesis and production of
CC   neutrophils, granulocytes, or platelets, this may be useful during
CC   chemotherapy.  IL-17 homologues have at least one activity selected
CC   from induction of cytotoxic T cells, induction of lymphokine-activated
CC   killer cell proliferation or a B or T cell stimulation.  The IL-17
CC   homologue may also be used to treat viral or bacterial infections,
CC   immune related diseases, anemia, leukemia, thrombocytopenia, uremia,
CC   Von Willebrand disease,  postoperative cardiovascular dysfunction,
CC   treatment of AIDS (acquired immune deficiency syndrome)-related bone
CC   marrow failure, and inflammatory diseases of the gastrointestinal
CC   system, joints, and lungs.
XX
SQ   Sequence   197 AA;
```

```
  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT   5
AAY44460
ID   AAY44460 standard; Protein; 197 AA.
XX
AC   AAY44460;
XX
DT   27-MAR-2000  (first entry)
XX
DE   Human Interleukin 17C, PRO1122 polypeptide.
XX
KW   Interleukin; IL-17C; PRO1122 polypeptide; clone DNA62377-1381-1; UNQ561;
KW   cytokine IL-17; cytotoxic T-lymphocyte-associated antigen 8; CTLA-8;
KW   hybridisation probe; antagonist; degenerative cartilaginous disorder;
KW   agonist; diagnose; therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /label= Signal_peptide
FT   Protein         19..197
FT                   /label= Mature_IL-17C_polypeptide
FT                   /note= "Used to treat degenerative cartilaginous
FT                   disorder"
FT   Misc-difference 109
FT                   /note= "Conserved Trp residue"
FT   Misc-difference 129
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 134
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 163
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 189
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 191
FT                   /note= "Conserved Cys residue"
XX
PN   WO9960127-A2.
XX
PD   25-NOV-1999.
XX
PF   14-MAY-1999;   99WO-US10733.
XX
PR   15-MAY-1998;   98US-0085579.
PR   23-DEC-1998;   98US-0113621.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Chen J,  Filvaroff E,  Goddard A,  Gurney AL,  Li H,  Wood WI;
XX
DR   WPI; 2000-116314/10.
DR   N-PSDB; AAZ29728.
XX
PT   New polypeptides designated PRO1031 and PRO1122 used to treat a
PT   degenerative cartilaginous disorder -
XX
PS   Claim 23; Fig 3; 141pp; English.
XX
CC   The present sequence is the human PRO1122 polypeptide, also referred to
CC   as UNQ561, and as interleukin-17C (IL-17C), encoded by
CC   clone DNA62377-1381-1. This sequence has identity with the
CC   cytokine IL-17 and cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8)
CC   and has leucine zipper pattern. PRO1122 is expressed in pancreas, small
CC   intestine, stomach and testis also. It shares about 26-28% amino acid
CC   identity with IL-17 and IL-17B. The entire coding region of IL-17C can
CC   be used as hybridisation probe. The PRO1122 polypeptide, agonist or
CC   antagonist, is used to diagnose and treat a degenerative cartilaginous
CC   disorder.
XX
SQ   Sequence   197 AA;


  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT   6
AAY53892
ID   AAY53892 standard; Protein; 197 AA.
XX
AC   AAY53892;
XX
DT   13-MAR-2000  (first entry)
XX
DE   Amino acid sequence of human interleukin-21.
XX
KW   Human; interleukin-22; IL-22; IL-21; immune system disorder;
KW   immune cell chemotaxis; haematopoietic cell disorder;
KW   haemostatic activity; thrombolytic activity; autoimmune disorder; asthma;
KW   respiratory problem; organ rejection; graft-versus-host disease; GVHD;
KW   inflammation; hyperproliferative disorder; tissue regeneration;
KW   embryonic stem cell differentiation; embryonic stem cell proliferation;
KW   haematopoietic lineage; allergic asthma.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /note= "signal peptide"
FT   Domain          34..40
FT                   /note= "conserved domain V"
FT   Domain          63..68
FT                   /note= "conserved domain VI"
FT   Domain          104..109
FT                   /note= "conserved domain VII"
FT   Domain          113..121
```

```
FT                   /note= "conserved domain I"
FT   Domain          129..134
FT                   /note= "conserved domain II"
FT   Domain          156..162
FT                   /note= "conserved domain III"
FT   Domain          185..192
FT                   /note= "conserved domain IV"
XX
PN   WO9961617-A1.
XX
PD   02-DEC-1999.
XX
PF   27-MAY-1999;   99WO-US11644.
XX
PR   29-MAY-1998;   98US-0087340.
PR   10-SEP-1998;   98US-0099805.
PR   30-APR-1999;   99US-0131965.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ebner R;
XX
DR   WPI; 2000-072622/06.
DR   N-PSDB; AAZ36836.
XX
PT   Novel polynucleotides used to develop products for treating e.g. immune
PT   disorders, blood disorders, autoimmune disorders, allergies,
PT   inflammation, hyperproliferative disorders or infections  -
XX
PS   Claim 26; Fig 6A-B; 170pp; English.
XX
CC   The present sequence represents a human interleukin-21 (IL-21)
CC   protein. The specification also describes IL-22 polynucleotides and
CC   polypeptides. The IL-21 polynucleotide was isolated from a cDNA library
CC   of apoptotic T-cells. IL-21 and IL-22 may be useful in treating
CC   deficiencies or disorders of the immune system, by activating or
CC   inhibiting the proliferation, differentiation, or mobilization
CC   (chemotaxis) of immune cells, treating or detecting deficiencies or
CC   disorders of haematopoietic cells, to modulate haemostatic or
CC   thrombolytic activity, in treating or detecting autoimmune disorders,
CC   treating asthma (particularly allergic asthma) or other respiratory
CC   problems, to treat and/or prevent organ rejection or graft-versus-host
CC   disease (GVHD), to modulate inflammation, to treat or detect
CC   hyperproliferative disorders, to treat or detect infectious agents, to
CC   differentiate, proliferate and attract cells, leading to the
CC   regeneration of tissues, IL-21 and IL-22 may also increase or decrease
CC   the differentiation or proliferation of embryonic stem cells and
CC   haematopoietic lineage, may be used to modulate mammalian
CC   characteristics.
XX
SQ   Sequence   197 AA;


  Query Match             100.0%;  Score 1073;  DB 21;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy      61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy     121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy     181 EFIHVPVGCTCVLPRSV 197
           |||||||||||||||||
Db     181 efihvpvgctcvlprsv 197


RESULT   7
AAG66121
ID   AAG66121 standard; Protein; 197 AA.
XX
AC   AAG66121;
XX
DT   13-MAR-2002  (first entry)
XX
DE   Human interleukin (IL)-21 amino acid sequence.
XX
KW   Interleukin; IL-21; IL-22; immunosuppressive; cytostatic; thrombolytic;
KW   antiinflammatory; antibacterial; gene therapy; human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /note= "signal peptide"
FT   Protein         19..197
FT                   /note= "mature protein"
FT   Domain          34..40
FT                   /note= "conserved domain V"
FT   Domain          63..68
FT                   /note= "conserved domain VI"
FT   Domain          104..109
FT                   /note= "conserved domain VII"
FT   Domain          113..121
FT                   /note= "conserved domain I"
FT   Domain          129..134
FT                   /note= "conserved domain II"
FT   Domain          156..162
FT                   /note= "conserved domain III"
FT   Domain          185..192
FT                   /note= "conserved domain IV"
XX
PN   US2001023070-A1.
XX
PD   20-SEP-2001.
XX
PF   08-DEC-2000; 2000US-0731816.
XX
PR   29-MAY-1998;   98US-087340P.
PR   30-APR-1999;   99US-131965P.
PR   09-DEC-1999;   99US-169837P.
PR   27-MAY-1999;   99US-0320713.
PR   27-MAY-1999;   99WO-US11644.
XX
PA   (EBNE/) EBNER R.
PA   (RUBE/) RUBEN S M.
XX
PI   Ebner R,  Ruben SM;
XX
DR   WPI; 2001-638470/73.
DR   N-PSDB; AAI67878.
XX
PT   New interleukin-21 and interleukin-22 polynucleotides and polypeptides,
PT   useful for treating, preventing or diagnosing e.g. disorders of
PT   hematopoietic cells, autoimmune disorders, or hyperproliferative
PT   diseases  -
XX
PS   Claim 26; Fig 6A-B; 87pp; English.
XX
CC   The invention relates to novel human proteins designated interleukin
CC   (IL)-21 and IL-22. The IL-21 and IL-22 polynucleotides can be used in
CC   linkage analysis as a marker for those specific chromosome, in chromosome
CC   mapping, to control gene expression through triple helix formation or
CC   antisense DNA or RNA, in gene therapy, in identifying individuals from
CC   minute biological samples, as an alternative to restriction fragment
CC   length polymorphism (RFLP) analysis, as polymorphic markers for forensic
CC   purposes, as molecular weight markers, or as diagnostic probes. IL-21 and
CC   IL-22 polypeptides can be used to treat, prevent or diagnose diseases of
CC   the immune system by activating or inhibiting the proliferation,
```

```
CC   differentiation or mobilization of immune cells, disorders of
CC   hematopoietic cells (e.g. ataxia, human immunodeficiency virus (HIV)
CC   infection, anemia, thrombocytopenia), autoimmune disorders (e.g. Grave's
CC   disease, systemic lupus erythematosus, ophthalmia), graft versus host
CC   disease, inflammation, hyperproliferative disorders, or infectious
CC   diseases. The polypeptides are useful for generating antibodies, which
CC   can be used to treat, inhibit or prevent diseases or conditions
CC   associated with aberrant expression and/or activity of IL-21 or IL-22.
CC   The present sequence represents the amino acid sequence of human IL-21.
XX
SQ   Sequence   197 AA;


  Query Match             100.0%;  Score 1073;  DB 22;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy      61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy     121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy     181 EFIHVPVGCTCVLPRSV 197
           |||||||||||||||||
Db     181 efihvpvgctcvlprsv 197


RESULT   8
AAU29247
ID   AAU29247 standard; Protein; 197 AA.
XX
AC   AAU29247;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PRO polypeptide sequence #224.
XX
KW   PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW   dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW   blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW   adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200168848-A2.
XX
PD   20-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US06520.
XX
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   03-MAR-2000; 2000US-187202P.
PR   06-MAR-2000; 2000US-186968P.
PR   14-MAR-2000; 2000US-189320P.
PR   14-MAR-2000; 2000US-189328P.
PR   15-MAR-2000; 2000WO-US06884.
PR   21-MAR-2000; 2000US-190828P.
PR   21-MAR-2000; 2000US-191007P.
PR   21-MAR-2000; 2000US-191048P.
PR   21-MAR-2000; 2000US-191314P.
PR   28-MAR-2000; 2000US-192655P.
PR   29-MAR-2000; 2000US-193032P.
PR   29-MAR-2000; 2000US-193053P.
PR   30-MAR-2000; 2000WO-US08439.
PR   04-APR-2000; 2000US-194449P.
PR   04-APR-2000; 2000US-194647P.
PR   11-APR-2000; 2000US-195975P.
PR   11-APR-2000; 2000US-196000P.
PR   11-APR-2000; 2000US-196187P.
PR   11-APR-2000; 2000US-196690P.
PR   11-APR-2000; 2000US-196820P.
PR   18-APR-2000; 2000US-198121P.
PR   18-APR-2000; 2000US-198585P.
PR   25-APR-2000; 2000US-199397P.
PR   25-APR-2000; 2000US-199550P.
PR   25-APR-2000; 2000US-199654P.
PR   03-MAY-2000; 2000US-201516P.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   05-JUN-2000; 2000US-209832P.
PR   28-JUL-2000; 2000WO-US20710.
PR   22-AUG-2000; 2000US-0644848.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Chen J,  Desnoyers L,  Goddard A,  Godowski PJ,  Gurney AL;
PI   Pan J,  Smith V,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-602746/68.
DR   N-PSDB; AAS46148.
XX
PT   Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT   presence of tumours, such as prostate and breast tumours, in mammals and
PT   to screen for modulators of the compounds -
XX
PS   Claim 11; Fig 448; 774pp; English.
XX
CC   Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
CC   The PRO polypeptides and their associated nucleic acids can be used to
CC   detect the presence of a tumour in a mammal by comparing the level of
CC   expression of a PRO polypeptide in a test sample of cells from the animal
CC   and a control sample of normal cells, whereby a higher level of
CC   expression in the test sample indicates the presence of a tumour in the
CC   mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
CC   and rabbits but are preferably human. The polypeptides can be used to
CC   stimulate tumour necrosis factor (TNF) alpha release from human blood,
CC   when contacted with it. A specific polypeptide can be used to stimulate
CC   the proliferation or differentiation of chondrocyte cells. The PRO
CC   proteins can be used to determine the presence of tumours and also
CC   susceptibility to tumour development, particularly adrenal, lung, colon,
CC   breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC   subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC   can be used for genetic analysis of individuals with genetic disorders.
XX
SQ   Sequence   197 AA;


  Query Match             100.0%;  Score 1073;  DB 22;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy      61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy     121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180
```

```
Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT   9
AAU04951
ID   AAU04951 standard; Protein; 197 AA.
XX
AC   AAU04951;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human Interleukin 17C ligand, IL-17C.
XX
KW   Human; Interleukin-17C ligand; IL-17C; agonist; antagonist;
KW   PRO1122; DNA 62377-1381-1; systemic lupus erythematosus;
KW   rheumatoid arthritis; osteoarthritis; diabetes mellitus;
KW   allergic disease; asthma; demyelinating disease;
KW   degenerative cartilaginous disorder; transplantation associated disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /label= Signal_peptide
FT   Region          3..25
FT                   /note= "Leucine zipper pattern"
FT   Protein         19..197
FT                   /label= Mature_IL_17C
FT   Region          32..38
FT                   /note= "N-myristoylation site"
FT   Region          55..61
FT                   /note= "N-myristoylation site"
FT   Region          99..125
FT                   /note= "Region homologous to IL-17"
FT   Region          112..121
FT                   /note= "Tyrosine kinase phosphorylation site"
FT   Region          133..139
FT                   /note= "N-myristoylation site"
XX
PN   WO200146420-A2.
XX
PD   28-JUN-2001.
XX
PF   20-DEC-2000; 2000WO-US34956.
XX
PR   23-DEC-1999;   99US-0172096.
PR   30-DEC-1999;   99WO-US31274.
PR   11-JAN-2000; 2000US-0175481.
PR   18-FEB-2000; 2000WO-US04341.
PR   02-MAR-2000; 2000WO-US05841.
PR   21-MAR-2000; 2000US-0191007.
PR   21-MAR-2000; 2000WO-US07532.
PR   02-JUN-2000; 2000WO-US15264.
PR   22-JUN-2000; 2000US-0213087.
PR   22-AUG-2000; 2000US-0644848.
PR   24-AUG-2000; 2000WO-US23328.
PR   24-OCT-2000; 2000US-0242837.
PR   10-NOV-2000; 2000WO-US30873.
PR   28-NOV-2000; 2000US-0253646.
PR   01-DEC-2000; 2000WO-US32678.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Chen J,  Filvaroff E,  Fong S,  Goddard A,  Godowski PJ,  Grimaldi CJ;
PI   Gurney AL,  Li H,  Hillan KJ,  Tumas D,  Van Lookeren M,  Vandlen RL;
PI   Watanabe CK,  Williams PM,  Wood WI,  Yansura DG;
XX
DR   WPI; 2001-451708/48.
DR   N-PSDB; AAS09510.
XX
PT   Novel PRO polypeptides homologous to interleukin-17, useful for the
PT   diagnosis and treatment of immune related disease e.g. rheumatoid
PT   arthritis and diabetes -
XX
PS   Claim 10; Fig 4; 188pp; English.
XX
CC   The sequence is PRO1122 which is the human Interleukin 17C ligand,
CC   IL-17C, encoded by DNA 62377-1381-1. A composition
CC   containing ant/agonists to the PRO polypeptides or individual components
CC   are useful for treating a mammal with an immune related disease, e.g.
CC   systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
CC   juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an
CC   idiopathic inflammatory myopathy, Sjogren's syndrome, systemic
CC   vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
CC   thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal
CC   disease, a demyelinating disease, an autoimmune or immune-mediated skin
CC   disease, contact dermatitis, an allergic disease e.g. food
CC   hypersensitivity, asthma, a transplantation associated disease, or a
CC   chronic inflammatory demyelinating polyneuropathy. Treating a
CC   degenerative cartilaginous disorder comprises administering a PRO1031 or
CC   PRO1122 polypeptide agonist, or antagonist to the mammal. Numerous
CC   examples of the diseases and disorders are given in the specification.
XX
SQ   Sequence  197 AA;


  Query Match             100.0%;  Score 1073;  DB 22;  Length 197;
  Best Local Similarity   100.0%;  Pred. No. 4.6e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT  10
AAY44485
ID   AAY44485 standard; Protein; 206 AA.
XX
AC   AAY44485;
XX
DT   27-MAR-2000  (first entry)
XX
DE   Human Interleukin 17C with C-terminal Gly(His)8 tag, IL-17C.his.
XX
KW   Interleukin; IL-17C.his; PRO1122 polypeptide; clone DNA62377-1381-1;
KW   immunoprecipitation; IL-17 receptor extracellular domain; IL-17R ECD;
KW   cytokine IL-17; hybridisation probe; antagonist; Gly(His)8 tag; agonist;
KW   degenerative cartilaginous disorder; diagnose; therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /label= Signal_peptide
FT   Protein         19..197
FT                   /label= Mature_IL-17C_polypeptide
FT                   /note= "Used to treat degenerative cartilaginous
FT                   disorder"
FT   Misc-difference 109
FT                   /note= "Conserved Trp residue"
```

```
FT   Misc-difference 129
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 134
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 163
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 189
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 191
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 198..206
FT                   /note= "C-terminal Gly(His)8 tag"
XX
PN   WO9960127-A2.
XX
PD   25-NOV-1999.
XX
PF   14-MAY-1999;   99WO-US10733.
XX
PR   15-MAY-1998;   98US-0085579.
PR   23-DEC-1998;   98US-0113621.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Chen J,  Filvaroff E,  Goddard A,  Gurney AL,  Li H,  Wood WI;
XX
DR   WPI; 2000-116314/10.
XX
PT   New polypeptides designated PRO1031 and PRO1122 used to treat a
PT   degenerative cartilaginous disorder -
XX
PS   Example 11; Page 138-139; 141pp; English.
XX
CC   The present sequence is the human PRO1122 polypeptide, with a C-terminal
CC   Gly(His)8 tag, IL-17C.his, derived from the clone DNA62377-1381-1.
CC   This sequence is used in a competitive binding experiment for the
CC   immunoprecipitation of IL-17 receptor extracellular domain (IL-17R ECD).
CC   The entire coding region of IL-17C can be used as hybridisation probe.
CC   The PRO1122 polypeptide, agonist or antagonist, is used to diagnose and
CC   treat a degenerative cartilaginous disorder.
XX
SQ   Sequence   206 AA;


  Query Match            100.0%;  Score 1073;  DB 21;  Length 206;
  Best Local Similarity  100.0%;  Pred. No. 4.9e-109;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqslvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT  11
AAY44462
ID   AAY44462 standard; Protein; 425 AA.
XX
AC   AAY44462;
XX
DT   27-MAR-2000  (first entry)
XX
DE   Human Interleukin 17C-IgG1 Fc fusion protein, hIL-17C.fc.
XX
KW   Interleukin; IL-17C.fc; fusion protein; PRO1122 polypeptide; cytokine;
KW   human IgG1; fluoresence-activated cell sorter analysis; FACS;
KW   Tumour Necrosis Factor-alpha; TNF-alpha; leukemic monocyte; THP-1 cell.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..18
FT                   /label= Signal_peptide
FT   Protein         19..197
FT                   /label= Mature_IL-17C_polypeptide
FT                   /note= "Used to treat degenerative cartilaginous
FT                   disorder"
FT   Misc-difference 109
FT                   /note= "Conserved Trp residue"
FT   Misc-difference 129
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 134
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 163
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 189
FT                   /note= "Conserved Cys residue"
FT   Misc-difference 191
FT                   /note= "Conserved Cys residue"
FT   Region          197..425
FT                   /note= "Sequence derived from Fc region of human IgG1"
XX
PN   WO9960127-A2.
XX
PD   25-NOV-1999.
XX
PF   14-MAY-1999;   99WO-US10733.
XX
PR   15-MAY-1998;   98US-0085579.
PR   23-DEC-1998;   98US-0113621.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Chen J,  Filvaroff E,  Goddard A,  Gurney AL,  Li H,  Wood WI;
XX
DR   WPI; 2000-116314/10.
XX
PT   New polypeptides designated PRO1031 and PRO1122 used to treat a
PT   degenerative cartilaginous disorder -
XX
PS   Example 12; Page 129-130; 141pp; English.
XX
CC   The present sequence is the human IL-17C.fc fusion protein, derived from
CC   PRO1122 polypeptide and the Fc region of human IgG1. The cytokine IL-17C
CC   can be used to induce the release of TNF-alpha from human leukemic
CC   monocytic, THP-1 cells. The fusion protein, IL-17C.fc is used to identify
CC   the binding of IL-17C to THP-1 cells, using fluoresence-activated cell
CC   sorter analysis (FACS).
XX
SQ   Sequence   425 AA;


  Query Match            100.0%;  Score 1073;  DB 21;  Length 425;
  Best Local Similarity  100.0%;  Pred. No. 1.3e-108;
  Matches  197;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQ 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 mtllpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgq 60

Qy     61 ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 alpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedry 120

Qy    121 PQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHT 180
```

```
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 pqklafaeclcrgcidartgretaalnsvrllqslllvlrrrpcsrdgsglptpgafafht 180

Qy    181 EFIHVPVGCTCVLPRSV 197
          |||||||||||||||||
Db    181 efihvpvgctcvlprsv 197


RESULT  12
AAE08676
ID   AAE08676 standard; Protein; 227 AA.
XX
AC   AAE08676;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein.
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         5..48
FT                   /label= Signal_peptide
FT   Protein         49..227
FT                   /label= Mature_human_IL-17_like protein
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
DR   N-PSDB; AAD15291.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 14; Fig 1A; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like protein.
XX
SQ   Sequence   227 AA;


  Query Match             99.1%;  Score 1063;  DB 22;  Length 227;
  Best Local Similarity   100.0%;  Pred. No. 6.9e-108;
  Matches  195;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy     63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy    123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    153 klafaeclcrgcidartgretaalnsvrllqslllvlrrrpcsrdgsglptpgafafhtef 212

Qy    183 IHVPVGCTCVLPRSV 197
          |||||||||||||||
Db    213 ihvpvgctcvlprsv 227


RESULT  13
AAE08680
ID   AAE08680 standard; Protein; 227 AA.
XX
AC   AAE08680;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Ile).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 47
FT                   /note= "Wild-type Leu substituted with Ile"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
```

```
PS   Claim 18; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Ile).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.9%;  Score 1061;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 1.1e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||:||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtciahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  14
AAE08682
ID   AAE08682 standard; Protein; 227 AA.
XX
AC   AAE08682;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Met).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX

FH   Key             Location/Qualifiers
FT   Misc-difference 47
FT                   /note= "Wild-type Leu substituted with Met"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection -
XX
PS   Claim 18; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Met).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.9%;  Score 1061;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 1.1e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||:||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtcmahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212
```

```
Qy    183 IHVPVGCTCVLPRSV 197
          ||||||||||||||||
Db    213 ihvpvgctcvlprsv 227


RESULT  15
AAE08681
ID   AAE08681 standard; Protein; 227 AA.
XX
AC   AAE08681;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Val).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 47
FT                   /note= "Wild-type Leu substituted with Val"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 18; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Val).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.8%;  Score 1060;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 1.5e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          |||||||||||||:||||||||||||||||||||||||||||||||||||||||||||||
Db     33 llpgllfltwlhtcvahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy     63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy    123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy    183 IHVPVGCTCVLPRSV 197
          ||||||||||||||
Db    213 ihvpvgctcvlprsv 227


RESULT  16
AAE08685
ID   AAE08685 standard; Protein; 227 AA.
XX
AC   AAE08685;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Glu110Asp).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 110
FT                   /note= "Wild-type Glu substituted with Asp"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 19; Page -; 117pp; English.
```

```
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Glu110Asp).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match            98.8%;  Score 1060;  DB 22;  Length 227;
  Best Local Similarity  99.5%;  Pred. No. 1.5e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||:|||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrhdrpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  17
AAE08684
ID   AAE08684 standard; Protein; 227 AA.
XX
AC   AAE08684;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Phe).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 47
FT                   /note= "Wild-type Leu substituted with Phe"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection -
XX
PS   Claim 18; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Phe).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match            98.7%;  Score 1059;  DB 22;  Length 227;
  Best Local Similarity  99.5%;  Pred. No. 1.9e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtcfahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
```

```
          ||||||||||||||||
Db    213 ihvpvgctcvlprsv 227


RESULT  18
AAE08687
ID   AAE08687 standard; Protein; 227 AA.
XX
AC   AAE08687;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Tyr141Phe).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 141
FT                   /note= "Wild-type Tyr substituted with Phe"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 20; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Tyr141Phe).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.7%;  Score 1059;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 1.9e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||:||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwrfrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           ||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  19
AAE08679
ID   AAE08679 standard; Protein; 227 AA.
XX
AC   AAE08679;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Nle).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 47
FT                   /label= Nle
FT                   /note= "Wild-type Leu substituted with Nle"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 18; Page -; 117pp; English.
```

```
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Nle).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.6%;  Score 1058;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 2.4e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtcxahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  20
AAE08683
ID   AAE08683 standard; Protein; 227 AA.
XX
AC   AAE08683;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Leu47Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
     .  '
FT   Misc-difference 47
FT                   /note= "Wild-type Leu substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection
XX
PS   Claim 18; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Leu47Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.6%;  Score 1058;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 2.4e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtcaahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
```

```
          ||||||||||||||||
Db    213 ihvpvgctcvlprsv 227


RESULT  21
AAE08686
ID   AAE08686 standard; Protein; 227 AA.
XX
AC   AAE08686;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Tyr141Trp).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 141
FT                   /note= "Wild-type Tyr substituted with Trp"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 20; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Tyr141Trp).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.6%;  Score 1058;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 2.4e-107;
  Matches  194;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||:||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwrwrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  22
AAE08690
ID   AAE08690 standard; Protein; 227 AA.
XX
AC   AAE08690;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Pro151Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 151
FT                   /note= "Wild-type Pro substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 21; Page -; 117pp; English.
XX
```

CC The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Pro151Ala).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

```
  Query Match             98.3%;  Score 1055;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 5.2e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedryaq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
          |||||||||||||||
Db     213 ihvpvgctcvlprsv 227
```

RESULT 23
AAE08688
ID AAE08688 standard; Protein; 227 AA.
XX
AC AAE08688;
XX
DT 15-NOV-2001 (first entry)
XX
DE Human interleukin (IL)-17 like protein mutant (Tyr141Thr).
XX
KW Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW multiple sclerosis; graft versus host disease; inflammatory disease;
KW asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 141
FT /note= "Wild-type Tyr substituted with Thr"
XX
PN WO200159120-A2.
XX
PD 16-AUG-2001.
XX
PF 07-FEB-2001; 2001WO-US03916.
XX
PR 08-FEB-2000; 2000US-0180864.
PR 27-NOV-2000; 2000US-0722920.
XX
PA (AMGE-) AMGEN INC.
XX
PI Jing S, Bass MB;
XX
DR WPI; 2001-529841/58.
XX
PT Novel interleukin-17 like polypeptides and nucleic acid molecules
PT encoding them useful for diagnosis, prevention and treatment of
PT inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT rejection -
XX
PS Claim 20; Page -; 117pp; English.
XX
CC The present invention relates to interleukin (IL)-17 like polypeptides
CC and nucleic acids encoding them. IL-17 like protein is useful for
CC identifying binding partners, agonists and antagonists which can be used
CC for treating one or more diseases or disorders and for cloning IL-17
CC like receptors, using an expression cloning strategy. Radiolabelled or
CC affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC identify a cell type or cell line or tissue that express IL-17 like
CC receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC affinity ligand to identify and isolate from an expression library the
CC subset of cells which express the IL-17 like receptors on their surface.
CC IL-17 like protein, agonist and antagonist are useful for treating acute
CC and chronic inflammation such as rheumatic diseases, graft versus host
CC disease and multiple sclerosis. IL-17 like antagonists are useful for
CC treating and preventing inflammatory disease, autoimmune disease,
CC allergies, asthma and organ or graft rejection in a patient and also
CC for inhibiting T cell proliferation and/or activation, in vivo B cell
CC proliferation or immunoglobulin secretion, and for blocking the effects
CC of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC gene therapy and for mapping the location of the IL-17 like gene and
CC related genes on chromosomes, as hybridisation probes in diagnostic
CC assays. Non-human animals in which the promoter for one or more of IL-17
CC like protein is either activated or inactivated are useful for drug
CC candidate screening. The present sequence is human IL-17 like
CC protein mutant (Tyr141Thr).
CC Note: The present sequence is not shown in the specification, but is
CC derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC (AAE08676), shown in figure 1A.
XX
SQ Sequence 227 AA;

```
  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwrtrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
          |||||||||||||||
```

```
Db    213 ihvpvgctcvlprsv 227


RESULT  24
AAE08689
ID   AAE08689 standard; Protein; 227 AA.
XX
AC   AAE08689;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Tyr141Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 141
FT                   /note= "Wild-type Tyr substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 20; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Tyr141Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwrsrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  25
AAE08691
ID   AAE08691 standard; Protein; 227 AA.
XX
AC   AAE08691;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Pro151Gly).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 151
FT                   /note= "Wild-type Pro substituted with Gly"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 21; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
```

```
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Pro151Gly).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrygq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  26
AAE08693
ID   AAE08693 standard; Protein; 227 AA.
XX
AC   AAE08693;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys159Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 159
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 22; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys159Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaealcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227
```

```
RESULT  27
AAE08695
ID   AAE08695 standard; Protein; 227 AA.
XX
AC   AAE08695;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys161Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 161
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 23; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys161Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 ilpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclargcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
          |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  28
AAE08697
ID   AAE08697 standard; Protein; 227 AA.
XX
AC   AAE08697;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys164Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 164
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 24; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
```

```
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys164Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgaidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  29
AAE08699
ID   AAE08699 standard; Protein; 227 AA.
XX
AC   AAE08699;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys193Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 193
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection -
XX
PS   Claim 25; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys193Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpasrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227
```

```
RESULT  30
AAE08701
ID   AAE08701 standard; Protein; 227 AA.
XX
AC   AAE08701;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys219Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 219
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 26; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys219Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           ||||||| ||||||||
Db     213 ihvpvgatcvlprsv 227


RESULT  31
AAE08703
ID   AAE08703 standard; Protein; 227 AA.
XX
AC   AAE08703;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys221Ala).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 221
FT                   /note= "Wild-type Cys substituted with Ala"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 27; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
```

```
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys221Ala).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.2%;  Score 1054;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 6.7e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
          ||||||||  ||||||
Db     213 ihvpvgctavlprsv 227


RESULT  32
AAE08692
ID   AAE08692 standard; Protein; 227 AA.
XX
AC   AAE08692;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys159Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens. .
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 159
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection -
XX
PS   Claim 22; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys159Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
          |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeslcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
          ||||||||||||||
Db     213 ihvpvgctcvlprsv 227
```

```
RESULT  33
AAE08694
ID   AAE08694 standard; Protein; 227 AA.
XX
AC   AAE08694;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys161Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 161
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 23; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys161Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclsrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  34
AAE08696
ID   AAE08696 standard; Protein; 227 AA.
XX
AC   AAE08696;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys164Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 164
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 24; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
```

```
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys164Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgsidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  35
AAE08698
ID   AAE08698 standard; Protein; 227 AA.
XX
AC   AAE08698;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys193Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 193
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection -
XX
PS   Claim 25; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys193Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpssrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||||||||||
Db     213 ihvpvgctcvlprsv 227


RESULT  36
```

```
AAE08700
ID   AAE08700 standard; Protein; 227 AA.
XX
AC   AAE08700;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys219Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 219
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 26; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys219Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;
```

```
  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           ||||||  ||||||||
Db     213 ihvpvgstcvlprsv 227
```

```
RESULT  37
AAE08702
ID   AAE08702 standard; Protein; 227 AA.
XX
AC   AAE08702;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human interleukin (IL)-17 like protein mutant (Cys221Ser).
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 221
FT                   /note= "Wild-type Cys substituted with Ser"
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 27; Page -; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
```

```
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is human IL-17 like
CC   protein mutant (Cys221Ser).
CC   Note: The present sequence is not shown in the specification, but is
CC   derived from the human IL-17 like protein referred to as SEQ ID NO:2
CC   (AAE08676), shown in figure 1A.
XX
SQ   Sequence   227 AA;


  Query Match             98.1%;  Score 1053;  DB 22;  Length 227;
  Best Local Similarity   99.5%;  Pred. No. 8.6e-107;
  Matches  194;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYSAEELPLGQAPPHLLARGAKWGQAL 62
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      33 llpgllfltwlhtclahhdpslrghphshgtphcysaeelplgqapphllargakwgqal 92

Qy      63 PVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQ 122
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      93 pvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedrypq 152

Qy     123 KLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTEF 182
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     153 klafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhtef 212

Qy     183 IHVPVGCTCVLPRSV 197
           |||||||| ||||||
Db     213 ihvpvgctsvlprsv 227


RESULT  38
AAE08677
ID   AAE08677 standard; Protein; 223 AA.
XX
AC   AAE08677;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human mature interleukin (IL)-17 like protein.
XX
KW   Human; interleukin; IL-17 like protein; rheumatic disease; gene therapy;
KW   multiple sclerosis; graft versus host disease; inflammatory disease;
KW   asthma; autoimmune disease; allergy; graft rejection; bone destruction;
KW   drug screening; antiinflammatory; immunosuppressive; antiasthmatic;
KW   neuroprotective; antirheumatic; antiallergic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..44
FT                   /label= Signal_peptide
FT   Misc-difference 62..64
FT                   /note= "These amino acid residues are absent in the
FT                   sequence shown in sequence listing of the specification"
FT   Protein         45..223
FT                   /label= Mature_human_IL-17_like protein
XX
PN   WO200159120-A2.
XX
PD   16-AUG-2001.
XX
PF   07-FEB-2001; 2001WO-US03916.
XX
PR   08-FEB-2000; 2000US-0180864.
PR   27-NOV-2000; 2000US-0722920.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Jing S,  Bass MB;
XX
DR   WPI; 2001-529841/58.
DR   N-PSDB; AAD15291.
XX
PT   Novel interleukin-17 like polypeptides and nucleic acid molecules
PT   encoding them useful for diagnosis, prevention and treatment of
PT   inflammatory, autoimmune disease, allergies, asthma and organ or graft
PT   rejection  -
XX
PS   Claim 15; Fig 2; 117pp; English.
XX
CC   The present invention relates to interleukin (IL)-17 like polypeptides
CC   and nucleic acids encoding them. IL-17 like protein is useful for
CC   identifying binding partners, agonists and antagonists which can be used
CC   for treating one or more diseases or disorders and for cloning IL-17
CC   like receptors, using an expression cloning strategy. Radiolabelled or
CC   affinity/activity-tagged IL-17 proteins are useful in binding assays to
CC   identify a cell type or cell line or tissue that express IL-17 like
CC   receptors. A radiolabelled or tagged IL-17 like protein is useful as an
CC   affinity ligand to identify and isolate from an expression library the
CC   subset of cells which express the IL-17 like receptors on their surface.
CC   IL-17 like protein, agonist and antagonist are useful for treating acute
CC   and chronic inflammation such as rheumatic diseases, graft versus host
CC   disease and multiple sclerosis. IL-17 like antagonists are useful for
CC   treating and preventing inflammatory disease, autoimmune disease,
CC   allergies, asthma and organ or graft rejection in a patient and also
CC   for inhibiting T cell proliferation and/or activation, in vivo B cell
CC   proliferation or immunoglobulin secretion, and for blocking the effects
CC   of IL-17 in inducing bone destruction. IL-17 like molecule is useful in
CC   gene therapy and for mapping the location of the IL-17 like gene and
CC   related genes on chromosomes, as hybridisation probes in diagnostic
CC   assays. Non-human animals in which the promoter for one or more of IL-17
CC   like protein is either activated or inactivated are useful for drug
CC   candidate screening. The present sequence is mature human IL-17 like
CC   protein.
XX
SQ   Sequence   223 AA;


  Query Match             96.4%;  Score 1034;  DB 22;  Length 223;
  Best Local Similarity   99.0%;  Pred. No. 1e-104;
  Matches  194;  Conservative    0;  Mismatches    0;  Indels    2;  Gaps    2;

Qy       3 LLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCYS-AEELPLGQAPPHLLARGAKWGQA 61
           |||||||||||||||||||||||||||||||||||| ||| ||||||||||||||||||||
Db      29 llpgllfltwlhtclahhdpslrghphshgtp-cyshaeelplgqapphllargakwgqa 87

Qy      62 LPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYP 121
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      88 lpvalvssleaashrgrherpsattqcpvlrpeevleadthqrsispwryrvdtdedryp 147

Qy     122 QKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLPTPGAFAFHTE 181
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     148 qklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglptpgafafhte 207

Qy     182 FIHVPVGCTCVLPRSV 197
           ||||||||||||||||
Db     208 fihvpvgctcvlprsv 223
```

```
RESULT  39
AAY53890
ID   AAY53890 standard; Protein; 87 AA.
XX
AC   AAY53890;
XX
DT   13-MAR-2000  (first entry)
XX
DE   Partial amino acid sequence of human interleukin-21.
XX
KW   Human; interleukin-21; IL-21; IL-22; immune system disorder;
KW   immune cell chemotaxis; haematopoietic cell disorder;
KW   haemostatic activity; thrombolytic activity; autoimmune disorder; asthma;
KW   allergic asthma; respiratory problem; organ rejection;
KW   graft-versus-host disease; GVHD; inflammation;
KW   hyperproliferative disorder; tissue regeneration;
KW   embryonic stem cell differentiation; embryonic stem cell proliferation;
KW   haematopoietic lineage.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          3..11
FT                   /note= "conserved domain I"
FT   Domain          19..24
FT                   /note= "conserved domain II"
FT   Domain          46..52
FT                   /note= "conserved domain III"
FT   Domain          75..82
FT                   /note= "conserved domain IV"
XX
PN   WO9961617-A1.
XX
PD   02-DEC-1999.
XX
PF   27-MAY-1999;   99WO-US11644.
XX
PR   29-MAY-1998;   98US-0087340.
PR   10-SEP-1998;   98US-0099805.
PR   30-APR-1999;   99US-0131965.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ebner R;
XX
DR   WPI; 2000-072622/06.
DR   N-PSDB; AAZ36834.
XX
PT   Novel polynucleotides used to develop products for treating e.g. immune
PT   disorders, blood disorders, autoimmune disorders, allergies,
PT   inflammation, hyperproliferative disorders or infections  -
XX
PS   Claim 25; Fig 1; 170pp; English.
XX
CC   The present sequence represents a partial human interleukin-21 (IL-21)
CC   protein. The specification also describes IL-22 polynucleotides and
CC   polypeptides. The IL-21 polynucleotide was isolated from a cDNA library
CC   of apoptotic T-cells. IL-21 and IL-22 may be useful in treating
CC   deficiencies or disorders of the immune system, by activating or
CC   inhibiting the proliferation, differentiation, or mobilization
CC   (chemotaxis) of immune cells, treating or detecting deficiencies or
CC   disorders of haematopoietic cells, to modulate haemostatic or
CC   thrombolytic activity, in treating or detecting autoimmune disorders,
CC   treating asthma (particularly allergic asthma) or other respiratory
CC   problems, to treat and/or prevent organ rejection or graft-versus-host
CC   disease (GVHD), to modulate inflammation, to treat or detect
CC   hyperproliferative disorders, to treat or detect infectious agents, to
CC   differentiate, proliferate and attract cells, leading to the regeneration
CC   of tissues, IL-21 and IL-22 may also increase or decrease the
CC   differentiation or proliferation of embryonic stem cells and
CC   haematopoietic lineage, may be used to modulate mammalian
CC   characteristics.
XX
SQ   Sequence   87 AA;


  Query Match             42.8%;  Score 459;  DB 21;  Length 87;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-42;
  Matches   86;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    112 RVDTDEDRYPQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLP 171
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      2 rvdtdedrypqklafaeclcrgcidartgretaalnsvrllqslvlrrrpcsrdgsglp 61

Qy    172 TPGAFAFHTEFIHVPVGCTCVLPRSV 197
          |||||||||||||||||||||||||
Db     62 tpgafafhtefihvpvgctcvlprsv 87


RESULT  40
AAG66119
ID   AAG66119 standard; Protein; 87 AA.
XX
AC   AAG66119;
XX
DT   13-MAR-2002  (first entry)
XX
DE   Human interleukin (IL)-21 partial amino acid sequence.
XX
KW   Interleukin; IL-21; IL-22; immunosuppressive; cytostatic; thrombolytic;
KW   antiinflammatory; antibacterial; gene therapy; human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          3..11
FT                   /note= "conserved domain I"
FT   Domain          19..24
FT                   /note= "conserved domain II"
FT   Domain          46..52
FT                   /note= "conserved domain III"
FT   Domain          75..82
FT                   /note= "conserved domain IV"
XX
PN   US2001023070-A1.
XX
PD   20-SEP-2001.
XX
PF   08-DEC-2000; 2000US-0731816.
XX
PR   29-MAY-1998;   98US-087340P.
PR   30-APR-1999;   99US-131965P.
PR   09-DEC-1999;   99US-169837P.
PR   27-MAY-1999;   99US-0320713.
PR   27-MAY-1999;   99WO-US11644.
XX
PA   (EBNE/) EBNER R.
PA   (RUBE/) RUBEN S M.
XX
PI   Ebner R,  Ruben SM;
XX
DR   WPI; 2001-638470/73.
DR   N-PSDB; AAI67876.
XX
PT   New interleukin-21 and interleukin-22 polynucleotides and polypeptides,
PT   useful for treating, preventing or diagnosing e.g. disorders of
PT   hematopoietic cells, autoimmune disorders, or hyperproliferative
PT   diseases  -
XX
PS   Claim 25; Fig 1; 87pp; English.
XX
CC   The invention relates to novel human proteins designated interleukin
CC   (IL)-21 and IL-22. The IL-21 and IL-22 polynucleotides can be used in
CC   linkage analysis as a marker for those specific chromosome, in chromosome
CC   mapping, to control gene expression through triple helix formation or
CC   antisense DNA or RNA, in gene therapy, in identifying individuals from
```

CC minute biological samples, as an alternative to restriction fragment
CC length polymorphism (RFLP) analysis, as polymorphic markers for forensic
CC purposes, as molecular weight markers, or as diagnostic probes. IL-21 and
CC IL-22 polypeptides can be used to treat, prevent or diagnose diseases of
CC the immune system by activating or inhibiting the proliferation,
CC differentiation or mobilization of immune cells, disorders of
CC hematopoietic cells (e.g. ataxia, human immunodeficiency virus (HIV)
CC infection, anemia, thrombocytopenia), autoimmune disorders (e.g. Grave's
CC disease, systemic lupus erythematosus, ophthalmia), graft versus host
CC disease, inflammation, hyperproliferative disorders, or infectious
CC diseases. The polypeptides are useful for generating antibodies, which
CC can be used to treat, inhibit or prevent diseases or conditions
CC associated with aberrant expression and/or activity of IL-21 or IL-22.
CC The present sequence represents the partial amino acid sequence of human
CC IL-21.
XX
SQ Sequence 87 AA;

Query Match 42.8%; Score 459; DB 22; Length 87;
Best Local Similarity 100.0%; Pred. No. 2.1e-42;
Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    112 RVDTDEDRYPQKLAFAECLCRGCIDARTGRETAALNSVRLLQSLLVLRRRPCSRDGSGLP 171
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      2 rvdtdedrypqklafaeclcrgcidartgretaalnsvrllqsllvlrrrpcsrdgsglp 61

Qy    172 TPGAFAFHTEFIHVPVGCTCVLPRSV 197
          |||||||||||||||||||||||||
Db     62 tpgafafhtefihvpvgctcvlprsv 87
```

Search completed: September 16, 2002, 15:45:32
Job time: 236 sec